Abstract 148P
Background
Clustering of the costimulatory TNF receptor superfamily member OX40 on activated T cells activates signaling pathways that enhance T-cell activation, survival, and proliferation. OX40 agonists in development requiring FcγR-mediated crosslinking to induce OX40 agonism have demonstrated limited clinical activity. We present the preclinical characterization of HexaBody-OX40 (GEN1055/BNT315), a novel OX40 agonist antibody designed to cluster OX40 independent of FcγR-mediated crosslinking to enhance antitumor T-cell responses.
Methods
Target binding characteristics and agonistic activity of HexaBody-OX40 were analyzed in vitro using binding assays, cell-based reporter assays, and functional assays using primary human T cells. Antitumor activity and pharmacodynamics of HexaBody-OX40 were assessed in vivo in MC38 tumor-bearing human OX40 knock-in mice.
Results
HexaBody-OX40 bound to activated OX40-expressing T cells. In contrast to other OX40 agonists, HexaBody-OX40 induced FcγR-independent OX40 agonist activity in a T-cell based reporter assay. In an assay using polyclonally stimulated human PBMCs, HexaBody-OX40 enhanced proliferation and activation of CD4+ and CD8+ T cells, and cytokine secretion. In this assay, OX40 agonistic activity in CD8+ T cells depended on the presence of CD4+ T cells. Furthermore, HexaBody-OX40 enhanced proliferation of antigen-specific CD8+ T cells overexpressing OX40. In vivo antitumor activity of HexaBody-OX40 in a syngeneic MC38 model in human OX40 knock-in mice was associated with peripheral T-cell proliferation and activation, increased percentages of tumor-specific CD8+ T cells, and an intratumoral increase in CD4+ T cells and Granzyme B+ cells.
Conclusions
In preclinical studies, HexaBody-OX40 exhibited FcγR-crosslinking-independent OX40 agonist activity, a unique mechanism of action that is distinct from other OX40 agonists. HexaBody-OX40 enhanced T-cell activation and proliferation in vitro and showed antitumor activity in vivo. A first-in-human clinical trial is planned to evaluate clinical safety and preliminary efficacy of HexaBody-OX40 in patients with advanced solid tumors.
Legal entity responsible for the study
The authors.
Funding
Genmab BV, BioNTech SE.
Disclosure
K. Kemper, M. van der Kroef, G. Zom, A. Gorlani, L. Guelen, D. Satijn, T. Ahmadi, E. Breij: Financial Interests, Personal, Full or part-time Employment: Genmab; Financial Interests, Personal, Stocks/Shares: Genmab BV. M. Köhne, K.B.B. Nuermberger, A. Krause, F. Gieseke, A. Muik, S. Fellermeier-Kopf, î Türeci, U. Sahin: Financial Interests, Personal, Full or part-time Employment: BioNtech SE; Financial Interests, Personal, Stocks/Shares: BioNTech SE. M. Russier, P. de Goeje: Financial Interests, Personal, Stocks/Shares: Genmab BV; Financial Interests, Personal, Full or part-time Employment: Genmab BV.
Resources from the same session
35P - Peripheral immunotype classification for monitoring Soft Tissue Sarcoma patients
Presenter: Jani Sofia Almeida
Session: Poster Display
36P - Expression of germinal center B cell- and Th17 cell-related transcripts are prognostic of soft-tissue sarcoma patient outcomes
Presenter: Giulia Petroni
Session: Poster Display
38P - Machine learning-based pathomics model to predict the infiltration of Treg and prognosis in IDH-wt GBM
Presenter: Shaoli Peng
Session: Poster Display
40P - The role of low avidity tumour-specific CD8+ T cells in immunotherapeutic response to anti-PD-1
Presenter: Doreen Lau
Session: Poster Display
41P - Contrasting drivers of response to immunotherapy across solid tumour types: results from analysis of >2500 cases
Presenter: Danwen Qian
Session: Poster Display
42P - TCCIA: A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy
Presenter: Jian-Guo Zhou
Session: Poster Display
43P - Immune and tumor cells expression of VISTA in a panel of cancer indications: A strategy to inform selection of patients treated with anti-VISTA
Presenter: Pierre Launay
Session: Poster Display
44P - Exploratory Analysis of Peripheral Pharmacodynamic (PD) Biomarkers After Sitravatinib (Sitra) and Tislelizumab (TIS) in Advanced Solid Tumors: SAFFRON-103
Presenter: Yi-Long Wu
Session: Poster Display
45P - Protein biomarkers associated with organ-specific immune-related toxicity and response to management identified by proteome analysis of extracellular vesicles from plasma
Presenter: Anders Kverneland
Session: Poster Display